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SObjective: Compensatory hyperhidrosis is a common devastating adverse effect after endoscopic thoracic sym-
pathectomy for patients undergoing surgical treatment of primary hyperhidrosis. We sought to determine
whether a correlation existed in our patient population between the level and extent of sympathetic chain resec-
tion and the subsequent development of compensatory hyperhidrosis.
Methods: All patients undergoing endoscopic thoracic sympathectomy in the T2-T3, T2-T4, T2-T5, or T2-T6
levels for palmar or axillary hyperhidrosis at the University of Iowa Hospital and Clinics (n¼ 97) from January
2004 to January 2013 were retrospectively reviewed.
Results: Differences in the preoperative patient characteristics were not statistically significant among the pa-
tients receiving T2-T3, T2-T4, T2-T5, or T2-T6 level resections. Of the 97 included patients, 28 (29%) expe-
rienced transient compensatory hyperhidrosis and 4 (4%) complained of severe compensatory hyperhidrosis
and required additional treatment. No operative mortalities occurred, and the morbidity was similar among
the groups.
Conclusions: Most patients had successful outcomes after undergoing extensive resection without changes
in the incidence of compensatory hyperhidrosis. Therefore, we recommend performing complete and
adequate resection for relief of symptoms in patients with primary hyperhidrosis. (J Thorac Cardiovasc Surg
2014;148:2673-6)Primary focal hyperhidrosis affects 1% to 3% of the popu-
lation and is characterized by increased perspiration out of
proportion to what is physiologically needed for thermoreg-
ulation.1 Primary focal hyperhidrosis is a chronic idiopathic
condition defined as focal, visible, and excessive sweating
of 6 months’ duration accompanied by 2 of the following
characteristics: bilateral and symmetric symptoms, onset
before age 25 years, impairment of daily activities, 1
episode per week, focal sweating that ceases during sleep,
and/or a family history of hyperhidrosis.2 It most commonly
affects the palms, axillae, and plantar surfaces.2 The patho-
physiology behind primary hyperhidrosis is not well under-
stood. It has been postulated that an abnormal or
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The Journal of Thoracic and Carhypothalamus or cerebral cortex causes increased auto-
nomic signaling to the eccrine sweat glands.3 Although
benign in nature, hyperhidrosis can cause soaking of papers,
clothes, and shoes, can lead to avoidance of social situations
and limitations in professional and physical activities, and
can result in emotional and psychological distress.
When topical and medical treatments have failed to
resolve excessive sweating, endoscopic thoracic sympa-
thectomy (ETS) is an effective surgical treatment of severe
primary palmar hyperhidrosis, with high patient satisfaction
rates. The most common devastating adverse effect after
ETS is compensatory hyperhidrosis (CH), defined as sub-
jectively increased sweating at parts of the body not
anatomically affected by the sympathectomy chain. CH is
thought to be a thermoregulatory response by which the
body compensates for the lack of perspiration at surgically
denervated regions by increasing perspiration in unaffected
areas, including the trunk, lumbar, groin, thigh, and popli-
teal regions.4 Widespread hyperhidrosis before surgery,
older age, greater body mass index, high ambient tempera-
ture, and a family history of primary hyperhidrosis are risk
factors for development of CH.5,6 The rates of CH cited in
published studies has ranged from 3% to 98%, depending
on how CH has been assessed.5 In attempts to decrease
the incidence of CH, many have suggested that limiting
the magnitude of resection of the sympathetic chain will
decrease the incidence of postoperative CH. However,diovascular Surgery c Volume 148, Number 6 2673
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Scontroversy remains regarding the appropriate level and
number of ganglia to be removed for the best outcome.
Our aim was to review the series of ETS cases performed
at our institution to determine whether the level of resection
influences the long-term results or overall outcomes of the
procedure.METHODS
From January 2004 to January 2013, all patients undergoing ETS in the
T2-T3, T2-T4, T2-T5, and T2-T6 levels for palmar or axillary hyperhidro-
sis at the University of Iowa Hospital and Clinics (n ¼ 97) were included
in a retrospective chart review. A total of 7 patients underwent ETS at
levels different from the 4 groups, none of whom reported CH, were
omitted from the present study owing to an inadequate sample size. The
data obtained included patient demographics, family history, site of pri-
mary hyperhidrosis, previous therapies, surgical details, outcome, and
complications. The patient demographics are listed in Table 1. Of the
90 patients, 39 (40%) experienced widespread hyperhidrosis with exces-
sive perspiration at the palmar, axillary, and plantar locations. Of the 97
total operations, 96 were bilateral ETS. One patient underwent a planned
staged procedure; he had previously undergone right-sided ETS, and only
left-sided ETS was performed at our institution. The level of sympathetic
ganglia removal is listed in Table 2. Seven different surgeons performed
the operations.
Operative Technique
ETS is performed as a bilateral procedure with the patient in the lateral
decubitus position using single lung ventilation with a double lumen tube.
The arm is mildly hyperextended for exposure of the axillae. Three 5-mm
thoracoscopic ports are used, with 2 placed in the axillae, 1 at the level of
the hairline for the highest port and the other in the fifth intercostal space
in the mid-axillary line. After the lung has been deflated, the lowest port is
inserted with a stab incision without the use of electrocautery or
spreading to prevent skin damage. The other 2 ports are placed in the
axillae, with the highest port placed first to not obstruct the view for
placement of the third port, 1 rib space below the highest port. The
lung is manipulated and compressed away from the spine to provide visu-
alization of the sympathetic chain. The first rib is identified, and the sec-
ond through sixth ribs are marked with electrocautery 3 to 5 cm away
from the chain laterally to ensure that the level of resection stays below
the first rib.
Next, the lowest level is identified, and the pleura immediately lateral to
the chain is opened from the lowest to the highest point. The lowest point of
the chain is then isolated and grasped with the 5-mm grasper proximally
and divided with electrocautery distally. With traction in a cranial and ante-
rior direction, the chain is gently removed using electrocautery to separate
the chain from the surrounding tissues and the intercostal vessels and
attachments.
Each ganglion is dissected using cautery until the second ganglion is
reached. The chain is then divided just below the second rib after removing
the ganglion sharply with scissors.
The area is monitored for hemostasis, and the pleura that laterally over-
lies the rib is superficially incised for a distance of 4 to 5 cm from the chain
laterally with electrocautery to divide any accessory nerves that might
remain. A 14F rubber catheter with multiple holes is inserted into the chest,2674 The Journal of Thoracic and Cardiovascular Surand the lung is reinflated, with suction applied to the catheter to allow full
re-expansion of the lung. The tube is then withdrawn on suction and with
positive pressure of 30 cm H2O applied to the lungs. The wounds are then
closed with tissue adhesives. A similar procedure is performed on the other
side. No chest tube or drain is used. The patient is discharged after a chest
radiograph to document pulmonary re-expansion.
Statistical Analysis
Univariate comparisons of the preoperative variables were performed
among the ETS T2-T3, T2-T4, T2-T5, and T2-T6 levels. Categorical vari-
ables were tested using the chi-square test, and continuous variables were
assessed using the analysis of variance test for associations. Univariate
comparison of the postoperative variables, including the incidence of
CH, was not performed owing to the low sample size in the T2-T3 and
T2-T4 resection groups. All analyses were performed using SPSS Statis-
tics, version 21 (IBM Corp, Armonk, NY).RESULTS
A total of 97 patients receiving ETS for palmar or axillary
hyperhidrosis were included in the present study. The sam-
ple consisted of 60 women and 37 men, with an average age
of 24 years (range, 13-66). The patients had hyperhidrosis at
1 sites, including 85 with palmar (88%), 65 with axillary
(67%), and 61 with plantar (63%) sites. Twelve patients
(12%) reported a family history of hyperhidrosis. All pa-
tients had been treated before surgery with medical man-
agement. This included oral glycopyrrolate (Robinul),
topical aluminum chloride hexahydrate 20% (Drysol),
iontophoresis with Drionic (General Medical Co, Pasadena,
Calif), injections of Botulinum toxin A, and oral clonidine.
The medical interventions had failed in all patients included
in the present study. The differences in the measured preop-
erative variables among the 4 groups were not statistically
significant.
Sympathetic levels T2-T6 were removed in 41 patients
(42%), T2-T5 in 36 patients (37%), T2-T4 in 11 patients
(11%), and T2-T3 in 9 patients (9%). No mortalities
occurred. The length of stay was<23 hours for all patients.
All patients experienced resolution of palmar hyperhidro-
sis. Additionally, of the 61 patients with plantar hyperhidro-
sis, 7 experienced complete resolution of symptoms, and 4
reported decreased symptoms. The morbidities included 4
cases of pneumothorax, 1 episode of subcutaneous emphy-
sema, in addition to CH. The pneumothorax and subcutane-
ous emphysema resolved spontaneously without chest tube
placement. No cases of Horner syndrome, excessive
bleeding, or infection were reported. Most patients were
satisfied with the results of the procedure.
CH was characterized as transient or severe. Transient
CH was defined as a minor increase in sweating present
for<90 days at any level, and severe CH was defined as
persistent sweating for 90 days requiring additional treat-
ment. Of the 97 patients, 28 (29%) experienced transient
CH. The breakdown of patients who experienced CH and
the location of transient CH stratified by the level of sympa-
thectomy is listed in Table 2.gery c December 2014
TABLE 2. Operative outcomes stratified by sympathectomy level
Variable
T2-T3
(n ¼ 9)
T2-T4
(n ¼ 11)
T2-T5
(n ¼ 36)
T2-T6
(n ¼ 41)
Severe CH 0 (0) 0 (0) 3 (8) 1 (2)
Transient CH 3 (33) 4 (36) 12 (33) 9 (22)
Location of transient CH
Chest 0 (0) 1 (9) 4 (11) 1 (2)
Abdomen 3 (33) 3 (27) 7 (19) 7 (17)
Lumbar region 3 (33) 2 (18) 10 (27) 4 (10)
Buttocks 0 (0) 0 (0) 2 (6) 0 (0)
Thighs 0 (0) 1 (9) 5 (14) 2 (5)
Popliteal 1 (11) 0 (0) 1 (3) 1 (2)
Data presented as n (%). CH, Compensatory hyperhidrosis.
TABLE 1. Preoperative patient characteristics stratified by
sympathectomy level
Variable
T2-T3
(n ¼ 9)
T2-T4
(n ¼ 11)
T2-T5
(n ¼ 36)
T2-T6
(n ¼ 41)
P
value
Female sex 6 (67) 5 (45) 21 (58) 28 (68) .522
Age (y) 17 (13-32) 20 (14-36) 21 (13-59) 21 (13-66) .288
BMI (kg/m2) 22 (20-28) 25 (19-33) 25 (18-47) 24 (20-36) .398
Family history 2 (22) 1 (9) 4 (11) 5 (12) .888
Primary symptoms
Axillary 6 (67) 6 (55) 24 (67) 29 (71) .787
Palmar 8 (89) 10 (91) 30 (83) 37 (90) .803
Plantar 7 (78) 6 (55) 23 (64) 25 (61) .755
Widespread 5 (56) 3 (27) 13 (36) 18 (44) .546
Previous treatment
Botulinum toxin 1 (11) 8 (73) 11 (31) 20 (49) .235
Iontophoresis 4 (44) 2 (18) 10 (28) 11 (27) .622
Data presented as median (range) for continuous variables or n (%) for categorical
variables. BMI, Body mass index.
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SFour patients (4%) complained of severe CH and
required additional treatment. One patient with T2-T6
ETS had CH affecting the abdomen, lower back, and
thighs, with extremely dry hands, axillae, and upper torso.
Documentation of the patient’s subsequent medical treat-
ment was unavailable. Three patients with T2-T5 ETS
experienced severe CH. The first had severe CH from the
nipple line to the feet that was managed postoperatively
with oral glycopyrrolate, topical aluminum chloride hexa-
hydrate 20%, and multiple Botulinum toxin A injections.
The second and third patients with severe CH reported
sweating on the trunk, requiring additional treatment with
oral glycopyrrolate and topical aluminum chloride hexahy-
drate 20%.DISCUSSION
For patients with medically refractory palmar hyperhi-
drosis, ETS will successfully resolve the symptoms in
almost every patient.7 The most devastating common
complication after ETS is CH, with an incidence reported
at 3% to 98%.5 Because the goal of ETS is to improve
the patient’s quality of life, complications should be mini-
mized or eliminated. Therefore, many have offered recom-
mendations to eliminate CH. However, controversy remains
regarding the specific surgical technique, level of resection,
and number of levels resected to minimize CH while maxi-
mizing the beneficial outcomes.
In the present study, 97 patients underwent ETS after
their hyperhidrosis had been deemed refractory to medical
management. Most patients at our institution received either
a T2-T6 or T2-T5 resection. This was more extensive than
that performed at many other institutions, which generally
resect or ablate 1 to 2 levels of the sympathetic chain.
Despite our larger resection area, the rate of transient CH
at our institution was 29%, similar to that reported inThe Journal of Thoracic and Carpublished studies of patient populations undergoing resec-
tion of only 1 or 2 ganglia.8-10 Similarly, the rate of
severe CH at our institution was 4.1%, in keeping with
the lowest rates reported in published studies.5
We defined severe CH as persistent excessive perspira-
tion lasting>90 days after surgery that required additional
treatment. In our experience, many patients will complain
of minor increased sweating in the initial weeks and months
after surgery. Patients with complaints of CH are given an
appointment 1 month after ETS and then asked to follow-
up at 3 and 6 months after ETS. Most of the patients with
CH will cancel their follow-up appointments because their
CH resolves spontaneously.
It has been postulated that CH is a thermoregulatory
response of the remaining sweat glands after denervation
of many of the upper extremity sweat glands by ETS.4
Many suggestions have been made to limit the number of
levels affected by ETS as much as possible. It was initially
thought that fibers from T2 alone innervate the eccrine
sweat glands in the upper extremity; thus, it was recom-
mended that T2 alone be divided.8 However, it was then
discovered that many patients have postganglionic nerves,
termed ‘‘accessory nerves of Kuntz,’’ leaving the sympa-
thetic chain at the T3 or T4 level and entering the brachial
plexus to innervate the upper extremity. This led to recom-
mendations to denervate, not only T2, but also T2-T3 or,
even, T2-T4.8
In a 2009 review of 282 patients who underwent ETS,
Miller and colleagues6 advocated division of the sympathetic
chain at theT2 level only.They reporteda significant decrease
in CH in the T2 division group compared with the T2-T4
group with multiple divisions of the chain. Of the T2 and
T2-T4 groups 13% and 34% experienced CH, respectively.6
In contrast, from the results of a 2009prospective randomized
control study of 60 patients undergoing ETS by division and
thermoablation of either the T2 or T3 ganglion, Yazbek and
colleagues8 recommended division of the T3 ganglion only
to reduce the incidence of CH. By 20 months of follow-up,
all the patients in their study reported some degree of CH.
The patients in the T2 group had significantly more severediovascular Surgery c Volume 148, Number 6 2675
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S(defined as visible, embarrassing, and requiring a change of
clothing) and nonsevere CH than those in the T3 group. How-
ever, no statistically significant difference was found in
patient-reported quality of life at 1, 6, or 20 months.8
Others have suggested interruption of the sympathetic
chain in multiple locations. In 2011, the Society of Thoracic
Surgeons conducted a review of >400 studies. They
concluded that patients with palmar hyperhidrosis should
undergo T3 and/or T4 sympathectomy; patients with T3
sympathectomy had increased CH, and patients with T4
sympathectomy had incomplete resolution of palmar sweat-
ing. For patients with widespread hyperhidrosis at the
palmar, axillary, and plantar sites, the Society of Thoracic
Surgeons has recommended T4 and T5 sympathectomy.5
Several studies have shown that division of T2, T3, or T4
or some combination reduces the incidence of CH. Howev-
er, many studies have suggested that CH occurs in many pa-
tients undergoing sympathectomy for hyperhidrosis,
regardless of the division level. Katara and colleagues10 re-
ported on 25 patients who had undergone T2 division on 1
side and T2-T3 division on the other side. These patients all
experienced resolution of their symptoms bilaterally, and
80% developed CH bilaterally, suggesting that the level
of chain interruption did not affect the development of
CH.10 Similarly, Leseche and colleagues11 reviewed 134
patients with multiple different levels of resection from
T1 to T5 and noted no significant correlation between the
extent of resection and the incidence or severity of CH.
Chwajol and colleagues12 also reviewed patients undergo-
ing various levels of resection from T2 to T4 and concluded
that no difference was present in the incidence of CH by the
level of resection. The only difference they noted was a sig-
nificant decrease in severe, debilitating CH in the T3 resec-
tion group.12 In a 2008 review of 87 studies, Kopelman and
Hashmonai13 studied the effect of multiple combinations of
T1, T2, T3, T4, and T5 sympathectomy by various tech-
niques. They concluded that limiting the level of sympa-
thetic ablation did not decrease the incidence of CH.13
Thus, in several relatively large studies considering multi-
ple combinations of different chain resections, no difference
was found in the incidence of CH.
The primary shortcomings of our study were the retro-
spective nature and the small sample size for the T2-3 and
T2-T4 groups. The patients in the present study were not
randomized to a resection group and paired for analysis,
limiting direct statistical comparisons. Additionally, the
disparity in the number of patients among the resection
groups negatively affected meaningful statistical analysis.
As mentioned, the extent of ganglion resection in our pa-2676 The Journal of Thoracic and Cardiovascular Surtients was larger than in many other studies; however, the
incidence of transient and severe CH was similar to that
consistently reported in published studies among those
advocating for resection of only 1 or 2 ganglia.CONCLUSIONS
The results of the present retrospective study have indicated
that in our patient population little differencewas present in the
outcomes or incidence of CH, regardless of the level or extent
of resection. Most of our patients underwent extensive resec-
tion, with a successful outcome and without a change in the
incidence of CH. Therefore, we do not recommend limiting
the resection level in an attempt to limit the incidence or
severity of CH. Because the extent of resection had no effect
on the occurrence of CH and other complications, we recom-
mend performing a complete and adequate resection for relief
of symptoms in patients with primary hyperhidrosis.References
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